STOCK TITAN

Progyny CEO Peter Anevski sells 236,630 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Progyny, Inc. CEO Peter Anevski exercised 185,134 stock options on November 10, 2026, at an exercise price of $0.91 per share, acquiring 185,134 common shares; the options were fully vested and exercisable. He also reported four common-stock sale entries totaling 236,630 shares: 120,213 at a weighted-average price of $35.6068 and 64,921 at $36.2851 under a Rule 10b5-1 plan entered into July 2, 2026, plus 33,437 at $35.6067 and 18,059 at $36.2851.

Insider Anevski Peter
Role CHIEF EXECUTIVE OFFICER
Sold 236,630 shs ($8.48M)
Approx. gross sale proceeds $8.48M
Approx. exercise cost $168K
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) F4 185,134 $0.00 $0.00
Exercise Common Stock 185,134 $0.91 $168K
Sale Common Stock F1, F2 120,213 $35.6068 $4.28M
Sale Common Stock F1, F3 64,921 $36.2851 $2.36M
Sale Common Stock F2 33,437 $35.6067 $1.19M
Sale Common Stock F3 18,059 $36.2851 $655K
Holdings After Transaction: Stock Option (Right to Buy) — 157,369 options (Direct); Common Stock — 710,972 shares (Direct)
Footnotes (4)
  1. F1. Shares sold pursuant to a Rule 10b5-1 trading plan entered into on July 2, 2026.
  2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote
  3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote
  4. F4. These options are fully vested and exercisable.
Shares acquired on exercise 185,134 shares November 10, 2026
Exercise price $0.91 per share Options exercised November 10, 2026
Shares sold 236,630 shares Four sale entries on November 10, 2026
Sale entry 120,213 shares at a weighted-average price of $35.6068 per share November 10, 2026
Sale entry 64,921 shares at a weighted-average price of $36.2851 per share November 10, 2026
Sale entry 33,437 shares at a weighted-average price of $35.6067 per share November 10, 2026
Sale entry 18,059 shares at a weighted-average price of $36.2851 per share November 10, 2026
Options remaining 157,369 options Following the November 10, 2026 exercise; expiration date August 3, 2027
Rule 10b5-1 trading plan regulatory
"Shares sold pursuant to a Rule 10b5-1 trading plan entered into July 2, 2026."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
fully vested and exercisable technical
"These options are fully vested and exercisable."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did PGNY CEO Peter Anevski sell, and at what prices?

Peter Anevski reported four sales totaling 236,630 shares on November 10, 2026: 120,213 at a weighted-average $35.6068, 64,921 at $36.2851, 33,437 at $35.6067, and 18,059 at $36.2851.

How many options did Peter Anevski have remaining after his PGNY exercise?

After exercising 185,134 options, Anevski reported 157,369 options remaining, with an expiration date of August 3, 2027.

What price ranges did PGNY’s reported sales cover?

The 120,213- and 33,437-share sale entries had reported weighted-average prices within $35.00 to $35.99, inclusive; the 64,921- and 18,059-share entries were within $36.00 to $36.43, inclusive.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Anevski Peter

(Last)(First)(Middle)
C/O PROGYNY, INC.
1359 BROADWAY, 2ND FLOOR

(Street)
NEW YORK NEW YORK 10018

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Progyny, Inc. [ PGNY ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
CHIEF EXECUTIVE OFFICER
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/10/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/10/2026M185,134A$0.91947,602D
Common Stock11/10/2026S(1)120,213D$35.6068(2)827,389D
Common Stock11/10/2026S(1)64,921D$36.2851(3)762,468D
Common Stock11/10/2026S33,437D$35.6067(2)729,031D
Common Stock11/10/2026S18,059D$36.2851(3)710,972D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$0.9111/10/2026M185,134 (4)08/03/2027Common Stock185,134$0157,369D
Explanation of Responses:
1. Shares sold pursuant to a Rule 10b5-1 trading plan entered into on July 2, 2026.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote
3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote
4. These options are fully vested and exercisable.
Remarks:
/s/ Mark Livingston, Attorney-in-Fact11/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading